Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...

The Scottish Medicines Consortium has recommended Astellas’s VEOZA (fezolinetant) 45 mg once daily for the treatment of ...

An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s ...

Grünenthal has received Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration for ...

Braun has appointed Sophie Spencer as Social Value & ESG Specialist, recognising her rapid impact since joining the company ...

Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its ...

Novartis has secured European Commission approval for Itvisma for the treatment of children aged two years and older, as well as teens and adults living with 5q spinal muscular at ...

Applications have opened for the ninth cohort of KQ Labs, the national accelerator for data‑driven health start‑ups delivered ...

Bayer has welcomed final draft guidance from NICE recommending finerenone for adults in England and Wales with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or ...

Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...

As a writer and as someone who is duty bound to occasionally make precise reference to the bill payer at 10 Downing Street, the use of square brackets, with a last-moment instruction to drop in the ...